Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis

S. Frankova, M. Lunova, H. Gottfriedova, R. Senkerikova, M. Neroldova, J. Kovac, E. Kieslichova, V. Lanska, P. Urbanek, J. Spicak, M. Jirsa, J. Sperl

. 2021 ; 16 (1) : e0244934. [pub] 20210107

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019472

Grantová podpora
NV16-27546A MZ0 CEP - Centrální evidence projektů

Liver stiffness is a reliable non-invasive predictor of Hepatic Venous Pressure Gradient (HVPG) above 10 mm Hg. However, it failed to predict higher thresholds of HVPG. Our aim was to investigate whether liver stiffness and selected previously published non-invasive blood biomarkers could predict higher HVPG thresholds in liver transplant candidates without ongoing alcohol use. One hundred and nine liver transplant candidates with liver cirrhosis of various aetiologies underwent direct HVPG measurement, liver stiffness measurement by 2D shear-wave elastography (Aixplorer Multiwave, Supersonic Imagine, France) and assessment of blood HVPG biomarkers (osteopontin, VCAM-1, IL-6, TNF-α, IL-1ra/IL-1F3 and ELF score). The correlation between liver stiffness and HVPG was linear up to 30 mm Hg of HVPG (r = 0.765, p < 0.0001). The regression lines had similar slopes for HVPG values below and above 16 mm Hg (p > 0.05) and the correlation in patients with HVPG <16 mm Hg (r = 0.456, p = 0.01) was similar to patients with HVPG ≥ 16 mm Hg (r = 0.499, p < 0.0001). The correlation was similar in the subgroup patients with alcoholic (r = 0.718, p < 0.0001), NASH (r = 0.740, p = 0.008), cryptogenic (r = 0.648, p = 0,0377), cholestatic and autoimmune (r = 0.706, p < 0.0001) and viral cirrhosis (r = 0.756, p < 0.0001). Liver stiffness distinguished patients with HVPG above 16, and 20 mm Hg with AUROCs 0.90243, and 0.86824, sensitivity 0.7656, and 0.7027, and specificity 0.9333, and 0.8750. All studied blood biomarkers correlated better with liver stiffness than with HVPG and their AUROCs did not exceed 0.8 at both HVPG thresholds. Therefore, a composite predictor superior to liver stiffness could not be established. We conclude that liver stiffness is a clinically reliable predictor of higher HVPG thresholds in non-drinking subjects with advanced liver cirrhosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019472
003      
CZ-PrNML
005      
20250402154234.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0244934 $2 doi
035    __
$a (PubMed)33411729
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fraňková, Soňa $u Department of Hepatogastroenterology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0329475
245    10
$a Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis / $c S. Frankova, M. Lunova, H. Gottfriedova, R. Senkerikova, M. Neroldova, J. Kovac, E. Kieslichova, V. Lanska, P. Urbanek, J. Spicak, M. Jirsa, J. Sperl
520    9_
$a Liver stiffness is a reliable non-invasive predictor of Hepatic Venous Pressure Gradient (HVPG) above 10 mm Hg. However, it failed to predict higher thresholds of HVPG. Our aim was to investigate whether liver stiffness and selected previously published non-invasive blood biomarkers could predict higher HVPG thresholds in liver transplant candidates without ongoing alcohol use. One hundred and nine liver transplant candidates with liver cirrhosis of various aetiologies underwent direct HVPG measurement, liver stiffness measurement by 2D shear-wave elastography (Aixplorer Multiwave, Supersonic Imagine, France) and assessment of blood HVPG biomarkers (osteopontin, VCAM-1, IL-6, TNF-α, IL-1ra/IL-1F3 and ELF score). The correlation between liver stiffness and HVPG was linear up to 30 mm Hg of HVPG (r = 0.765, p < 0.0001). The regression lines had similar slopes for HVPG values below and above 16 mm Hg (p > 0.05) and the correlation in patients with HVPG <16 mm Hg (r = 0.456, p = 0.01) was similar to patients with HVPG ≥ 16 mm Hg (r = 0.499, p < 0.0001). The correlation was similar in the subgroup patients with alcoholic (r = 0.718, p < 0.0001), NASH (r = 0.740, p = 0.008), cryptogenic (r = 0.648, p = 0,0377), cholestatic and autoimmune (r = 0.706, p < 0.0001) and viral cirrhosis (r = 0.756, p < 0.0001). Liver stiffness distinguished patients with HVPG above 16, and 20 mm Hg with AUROCs 0.90243, and 0.86824, sensitivity 0.7656, and 0.7027, and specificity 0.9333, and 0.8750. All studied blood biomarkers correlated better with liver stiffness than with HVPG and their AUROCs did not exceed 0.8 at both HVPG thresholds. Therefore, a composite predictor superior to liver stiffness could not be established. We conclude that liver stiffness is a clinically reliable predictor of higher HVPG thresholds in non-drinking subjects with advanced liver cirrhosis.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a pružnost $x fyziologie $7 D004548
650    _2
$a elastografie $x metody $7 D054459
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibróza $x patologie $7 D005355
650    _2
$a venae hepaticae $x patologie $7 D006503
650    _2
$a lidé $7 D006801
650    _2
$a portální hypertenze $x patologie $7 D006975
650    _2
$a lineární modely $7 D016014
650    _2
$a játra $x patologie $7 D008099
650    _2
$a jaterní cirhóza $x patologie $7 D008103
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a portální tlak $x fyziologie $7 D017082
650    _2
$a prospektivní studie $7 D011446
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a venózní tlak $x fyziologie $7 D014690
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lunova, Mariia $u Laboratory of Experimental Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Gottfriedova, Halima $u Department of Hepatogastroenterology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Senkerikova, Renata $u Department of Hepatogastroenterology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Charles University, First Faculty of Medicine, Prague, Czech Republic
700    1_
$a Neroldova, Magdalena $u Laboratory of Experimental Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kovac, Jozef $u Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kieslichova, Eva $u Anaesthesiology, Resuscitation and Intensive Care Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Lanska, Vera $u Department of Biostatistics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Urbanek, Petr $u Charles University, First Faculty of Medicine, Prague, Czech Republic $u Department of Internal Medicine, Central Military Hospital, Prague, Czech Republic
700    1_
$a Spicak, Julius $u Department of Hepatogastroenterology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Jirsa, Milan $u Laboratory of Experimental Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Charles University, First Faculty of Medicine, Prague, Czech Republic
700    1_
$a Sperl, Jan $u Department of Hepatogastroenterology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Charles University, First Faculty of Medicine, Prague, Czech Republic
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 16, č. 1 (2021), s. e0244934
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33411729 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20250402154231 $b ABA008
999    __
$a ok $b bmc $g 1690320 $s 1139918
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 16 $c 1 $d e0244934 $e 20210107 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NV16-27546A $p MZ0
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace